Recent Updates
Recently added Catalysts
TB

Tevogen Bio Holdings Inc.

TVGNFDA catalysts, PDUFA dates & pipeline intelligence
$5.9
▼ -0.4 · -6.35%

Financials

Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Quarterly Cash
Unlock full TVGN financials and dilution scoring
Quarter by quarter figures, cash trend and dilution risk.
Institutional-grade data · Cancel anytime
52W LOW $3.6452W HIGH $24.91
Volume
9.35 K
Value Traded
55.70 K
Short % Float
0.08%
Days to Cover
4.3
-1.67%Week
-8.39%1 Month
-12.59%3 Month
-38.61%6 Month
-71.45%1 Year
-98.82%All Time

Cash Data

Unlock TVGN cash and runway
  • Monthly Burn
  • Burn Trend
  • Dilution Risk
  • SEC Filing

Key Stats

Market Cap
405.20 M
EPS (TTM)
-6.06
P/E Ratio
-
Ent. Value
-
Total Shares
68.68 M
Float Shares
68.68 M
Insiders
0.00%
Institutions
0.09%

Upcoming Catalysts

FDA decisions, readouts and PDUFA dates · scored by probability of approval

Catalyst Drug / Treatment Stage Prob. of Approval Description Drug Type Therapeutic Area Source
Unlock every TVGN catalyst date and PoA score
Every FDA decision, readout and PDUFA date, with drug type, therapeutic area and a PoA score you can trade on.
Institutional-grade data · Cancel anytime
PoA blends historical approval base rates, trial design score and FDA review track record.

TVGN Catalyst Timeline

Dated clinical, regulatory and corporate events for Tevogen Bio Holdings Inc.

Catalyst Timeline

Dated clinical, regulatory & corporate events for Tevogen Bio Holdings Inc.

168Total events
2Upcoming
46Tier-1 (high impact)
2023 to 2029Coverage

Upcoming catalysts 2

TBD
T1Partnership / License
Subscribe to view catalyst details
TBD
T3Manufacturing Milestone
Subscribe to view catalyst details

Event history 50

▲Quarterly UpdateCorporate
Tevogen reports 17% YoY decline in operating loss for nine months ended September 30, 2026
●Quarterly UpdateCorporate
Insider ownership increased from 83% to 92%
▲Quarterly UpdateCorporate
Eliminated $7.6 million in liabilities related to a loan obligation
▲Debt Royalty FinancingCorporate
Tevogen eliminated $7.6 million in liabilities related to a loan obligation
▲Quarterly UpdateCorporate
Liabilities reduced from $99.9M (FY2023) to $14.8M as of September 30, 2026
●Management ChangeCorporate
Tevogen Bio Holdings Inc. changes name to Tevogen Inc.
▼Equity OfferingCorporate
Tevogen announces $3 million PIPE financing at $8 per prefunded warrant
◆Platform ValidationPreclinical
PredicTcell training nearing completion
◆Partnership / LicenseCorporate
Evaluating potential co-development partnerships for PredicTcell platform
▲Quarterly UpdateCorporate
Tevogen regains compliance with Nasdaq minimum bid price requirement
Unlock the full TVGN catalyst timeline
Every PDUFA date, readout, approval and corporate move, tiered by market impact and updated daily.
Institutional-grade data · Cancel anytime

Past FDA Catalysts and PDUFA Decisions

How TVGN actually traded into and out of each decision

Date Drug Catalyst Stage Reaction Event Move % Best Trade %
No matching catalysts
Unlock all TVGN historical catalysts
Institutional-grade data · Cancel anytime
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision

Drug Pipeline Intelligence

Pipeline Score
Pipeline Value
Valuation Signal
0
Drugs Scored
rNPV / MCap
Top Drug
Top 100%
Micro Cap
(rank 719 of 719)
Percentile Rank
Showing 0 of 1 assets
DrugIndicationPhasePTRSrNPVStatusEnrollVelocityDesignEst. CompletionML SignalLast Change
Unlock the TVGN pipeline intelligence model
PTRS, rNPV, enrollment velocity, trial design quality and ML risk signals for every asset above.
Institutional-grade data · Cancel anytime

Clinical Trial Results

Readouts, endpoints and source filings for every TVGN program

Drug Name Indication Phase Date Trial Results SummaryTitleSource
TVGN 489 COVID-19 and Long COVID2025-10-15The dose-finding clinical trial of TVGN 489 demonstrated a favorable safety profile, providing valuable insights for further development, although specific efficacy metrics or outcomes were not disclosed in the press release.Read MoreTevogen Updates on TVGN 489 Following Growing Long COVID Patient InterestRead More
Scroll for more · summaries link to the source press release
Unlock every TVGN trial readout
Institutional-grade data · Cancel anytime

Inside Trades

Unlock TVGN insider buying and selling
Monthly insider buys and sells against the stock price, with the insider sentiment reading.
Institutional-grade data · Cancel anytime
InsiderSideSharesPriceValueDate
Sordillo Victor J.DirectorGrant/Award 40,000 51,539 held$0.00 07/10/2026
Unlock the full TVGN insider trade log
Institutional-grade data · Cancel anytime

Hedge Fund 13F Activity

Fund % of Portfolio Current MV Shares Owned Activity
No hedge fund reported a 13F position in TVGN for Q3 2026.
Unlock every fund holding TVGN
Every 13F position with quarter over quarter share flow and average entry price.
Institutional-grade data · Cancel anytime
Unlock hedge fund flows in TVGN
Shares held by hedge funds each quarter, and who bought or sold.

Ownership Trends

Sign in to see TVGN ownership
Insider and institutional ownership, quarter by quarter.

TVGN Short Interest

Shares sold short, counted twice a month.

0.08%
Short % of Float
of tradable shares sold short
54.9K
Shares Sold Short
-1.0% vs prior count
4.3 Moderate
Days to Cover
trading days of normal volume to buy every short share back
12.7K
Avg Daily Volume
the average used for days to cover
Unlock TVGN short interest history
Two years of days to cover and shares sold short, with every count and its change.
Institutional-grade data · Cancel anytime

Options Data

Option Volume

Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg

Option Chain Statistics

ExpiryCall VolPut VolVol P/CCall OIPut OIOI P/CIV CallIV Call OI-WtdIV Call Vol-WtdIV PutIV Put OI-WtdIV Put Vol-Wtd
Unlock TVGN option chain statistics
Per-expiry call and put volume, open interest, put-call ratios and implied volatility.
Institutional-grade data · Cancel anytime

Real-Time Option Chain

CallsStrikePuts
LastVolOILastVolOI
No data available
Unlock the live TVGN option chain
Live calls and puts by strike: last price, volume and open interest for every expiry.
Institutional-grade data · Cancel anytime

Calls vs Puts by Expiry

CallsPutsLog scale
Unlock TVGN options analytics
Institutional-grade data · Cancel anytime

Competitive positioning

How TVGN ranks across every disease it competes in

Competitive Position is a premium feature
See how TVGN ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial

TVGN News

-TVGN
Nov 18, 2026
TVGNGeneral
▲ +5.9%on this news

Tevogen Highlights Significant Liability Reduction and Continued Insider Control

Tevogen Inc. reported a significant reduction in liabilities from $99.9 million in 2023 to $14.8 million as of September 30, 2026. Insider ownership rose to 92%, reflecting strong control by the management team. The company's loss from operations also decreased by 17%, indicating improved financial performance.

Read more →
-TVGN
Nov 9, 2026
TVGNGeneral

Tevogen Complements Capital Access with Two-Year Extension to Loan Agreement

Tevogen Inc. has extended its loan agreement with The Patel Family, LLP to May 2029, increasing its borrowing capacity to $28.6 million. This extension complements the company's existing ATM equity program, which allows for up to $50 million in sales. CEO Ryan Saadi emphasized a disciplined approach to financing.

Read more →
-TVGN
Oct 8, 2026
TVGNGeneral

UPDATE – Tevogen Signs Letter of Intent to Evaluate Potential Acquisition of HRK Healthcare LLC

Tevogen Inc. signed a non-binding letter of intent to evaluate acquiring HRK Healthcare LLC. The deal could expand its healthcare services arm and support a $100 million annual revenue target. CEO Ryan Saadi hopes to close the transaction by the end of the fourth quarter of 2026. The agreement remains subject to due diligence and customary closing conditions.

Read more →
-TVGN
Sep 30, 2026
TVGNGeneral

Tevogen Regains Compliance with Nasdaq Global Market Continued Listing Requirements

Tevogen Inc. announced it has regained compliance with Nasdaq's listing requirements. The company met the $50 million minimum market value of listed securities requirement. This follows a previous notice confirming compliance with the minimum market value of publicly held shares. All related Nasdaq compliance matters are now resolved.

Read more →
-TVGN
Jul 29, 2026
TVGNGeneral
▲ +6.3%on this news· ran to +26% by day 3

Tevogen Bio Holdings Inc. Becomes Tevogen Inc.

Tevogen Bio Holdings Inc. will officially operate as Tevogen Inc. starting July 30, 2026, following Board approval. This name change signifies the company's transition into a healthcare enterprise focused on integrating biotechnology, artificial intelligence, and healthcare services. The firm aims to enhance the affordability and accessibility of life-saving medicines while continuing to trade under the ticker symbols TVGN and TVGNW.

Read more →
-TVGN
Jul 14, 2026
TVGNGeneral

Tevogen Bio Announces 2026 Annual Meeting of Stockholders

Tevogen Bio Holdings Inc. has announced its 2026 Annual Meeting of Stockholders, scheduled for August 24, 2026. Stockholders of record as of July 23, 2026, will be eligible to vote. Proposals for consideration must be submitted by the same date, adhering to SEC rules and the company's bylaws. Tevogen aims to enhance healthcare accessibility through its various initiatives.

Read more →
-TVGN
Jun 9, 2026
TVGNGeneral

Tevogen Announces Formation of a Healthcare Services Initiative

Tevogen Bio Holdings Inc. has announced the formation of a healthcare services initiative aimed at expanding its revenue-generating capabilities. Led by interim head William Keane, the initiative may involve acquiring a Management Services Organization and a Contract Research Organization, potentially generating $100 million in annual revenue. This move aligns with Tevogen's mission to enhance healthcare affordability and access.

Read more →
-TVGN
May 28, 2026
TVGNGeneral
▲ +11.8%on this news

Tevogen Advances Strategic Acquisition Initiatives with Potential to Support Approximately $100 Million in Combined Annual Revenue

Tevogen Bio Holdings Inc. has announced progress in its strategic acquisition initiatives, potentially leading to approximately $100 million in combined annual revenue. The company aims to evolve into a financially self-sufficient healthcare enterprise by exploring acquisitions that complement its existing biotechnology and technology arms. While the initiatives present significant financial potential, they are dependent on due diligence and approvals, and their success is uncertain.

Read more →
-TVGN
May 21, 2026
TVGNGeneral
▲ +10.4%on this news· ran to -31% by day 3

Tevogen Signs Letter of Intent to Evaluate Potential Acquisition of a Management Services Organization

Tevogen Bio Holdings Inc. has signed a Letter of Intent to explore a potential acquisition of a Management Services Organization. This move is aimed at enhancing its healthcare infrastructure and supports the company's evolution into a revenue-generating entity. The CEO expressed that, if successful, the transaction could contribute to an estimated $100 million in annual revenue. However, the completion of the deal is contingent on due diligence, negotiation, and approval processes, which presents inherent uncertainties.

Read more →
-TVGN
May 18, 2026
TVGNGeneral
▲ +11.3%on this news· ran to +45% by day 3shared move

Letter to Shareholders from CEO Dr. Ryan Saadi

Tevogen Bio Holdings Inc. has reported a significant reduction in operational losses, with a 51% decline from 2024 to 2025. The company is advancing its strategic initiatives, including the Tevogen.AI project and expanding its cell therapy pipeline. CEO Dr. Ryan Saadi emphasized the importance of aligning long-term incentives with performance milestones while maintaining a focus on shareholder equity.

Read more →
-TVGN
May 12, 2026
TVGNGeneral

Tevogen Announces $3 Million Private Investment at $8 Per Share, a 14% Premium from Latest Market Close

Tevogen Bio Holdings Inc. has announced a $3 million private investment with The Patel Family, LLP, priced at a 14% premium to its latest closing price. This investment aims to enhance Tevogen's operational capabilities, support growth initiatives, and solidify its financial foundation. The financing agreement involves the issuance of 375,000 prefunded warrants, which will close on May 13, 2026. Tevogen's management expressed optimism about the financing's potential benefits in achieving significant revenue milestones.

Read more →
-TVGN
Apr 28, 2026
TVGNGeneral
▼ -7.3%on this news

Tevogen.AI Nears Completion of PredicTcell™ Training; Initiates Commercial Readiness and Debuts Internal Application Portal

Tevogen Bio Holdings Inc. has announced significant advancements in its AI initiative, Tevogen.AI, with the PredicTcell™ training algorithm nearing completion. The model has shown a 10% improvement in precision and the company is exploring partnerships to enhance its application. Additionally, an internal application portal has been developed to streamline workflows and support future commercial efforts.

Read more →
-TVGN
Mar 26, 2026
TVGNGeneral
▼ -5.6%on this newsshared move

Tevogen Advances Strategic CRO Evaluation to Expand Clinical Research Delivery Capabilities and Drive Revenue Growth

Tevogen Bio Holdings Inc. is evaluating a contract research organization (CRO) to enhance its clinical research capabilities. This potential transaction could generate over $20 million in annual revenue and support double-digit growth. The CEO highlighted the company's ambition to achieve a cash flow positive model while expanding its focus on oncology and rare diseases.

Read more →
-TVGN
Mar 25, 2026
TVGNGeneral

Tevogen Regains Compliance with Nasdaq Minimum Bid Price Requirement

Tevogen Bio Holdings Inc. has successfully regained compliance with Nasdaq's minimum bid price requirement after facing non-compliance in September 2025. The company aims to transform into a comprehensive healthcare enterprise by combining immunotherapy and artificial intelligence while exploring new strategic initiatives. These initiatives focus on enhancing patient access and affordability while aiming for a cash-flow-positive model. Tevogen's pipeline spans several therapeutic areas, reflecting its commitment to sustainable innovation in healthcare.

Read more →
-TVGN
Mar 18, 2026
TVGNConferences/Events

Tevogen CIO and Head of Tevogen.AI Mittul Mehta to Speak at Microsoft Fabric Community Conference (FabCon 2026)

Tevogen Bio Holdings Inc. announced that Mittul Mehta, the Chief Information Officer and Head of Tevogen.AI, will speak at the Microsoft Fabric Community Conference (FabCon 2026) in March 2026. His sessions will focus on the intersection of data engineering and artificial intelligence, addressing modernizing data architecture and building adaptive data pipelines. These themes align with Tevogen.AI's efforts to utilize advanced machine learning to improve biomedical discovery and patient treatment solutions. This participation highlights Tevogen's commitment to integrating cutting-edge technology in healthcare.

Read more →
-TVGN
Mar 13, 2026
TVGNGeneral
▼ -15.7%on this newsshared move

Tevogen Reaffirms Capital Discipline as Lead Investor Maintains Holdings and Company Limits Share Utilization

Tevogen has provided a strategic update emphasizing its commitment to capital discipline, including the decision to limit share utilization to no more than 1% of its authorized shares in the coming year. The lead investor has expressed strong confidence in Tevogen's growth potential and proprietary technology. Additionally, the company is evaluating acquisitions that could generate over $50 million in annual revenue and is considering a one-time special cash dividend based on future financial milestones. Tevogen's approach reflects a dedication to long-term value creation and operational efficiency.

Read more →
-TVGN
Mar 13, 2026
TVGNGeneral
▼ -15.7%on this newsshared move

Tevogen.AI Reports Advancements in PredicTcell™ Beta, Demonstrates Improved Precision Metrics and Expands Proprietary AI Infrastructure

Tevogen Bio Holdings Inc. has reported advancements in its artificial intelligence platform, Tevogen.AI, specifically in the PredicTcell™ model. The company achieved significant improvements in prediction accuracy, with recall increasing to 92% and precision rising to 48%. Additionally, Tevogen.AI has expanded its proprietary database to over 655 million peptide sequences, enabling more robust model training and target identification. The company plans to explore partnerships to advance its peptide candidates as predictive accuracy continues to improve.

Read more →
-TVGN
Mar 11, 2026
TVGNGeneral

Tevogen CEO Dr. Ryan Saadi Reaffirms Clinical Commitment During International Long COVID Awareness Month; Highlights Synergies of New Leadership Team and Digital Care Platform

Tevogen, led by CEO Dr. Ryan Saadi, has reiterated its commitment to clinical development during International Long COVID Awareness Month. The company is advancing its investigational T-cell therapy, TVGN 489, and evaluating the acquisition of the Sciometrix Clinicus platform for real-world monitoring of Long COVID patients. Recent proof-of-concept results show that all treated high-risk patients did not develop Long COVID. With plans to expand its HLA target coverage, Tevogen aims to enhance accessibility for a larger portion of the U.S. population.

Read more →
-TVGN
Mar 9, 2026
TVGNGeneral
▲ +6%on this newsshared move

Tevogen Names Leadership Team to Execute Diversified Growth Strategy

Tevogen Bio Holdings Inc. has appointed interim leaders across its core business sectors to implement a diversified growth strategy. This strategy aims to explore opportunities that could generate over $50 million in annual revenues, with expected closures by Q2 2026. The company is leveraging advanced technologies in healthcare, including AI and precision T cell therapies, to enhance its offerings.

Read more →

About Tevogen Bio Holdings Inc.

Warren, NJ 18 employees tevogen.com
Headquarters15 INDEPENDENCE BOULEVARD, SUITE #210, WARREN, NJ, 07059
BIOPHARMAWATCH ELITE
Trade the next TVGN catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $24/mo billed annually.
Cancel anytime